Lilly Japan moves into GP market with Cialis
In the wake of launching its erectile dysfunction drug Cialis (tadalafil) in Japan, US pharmaceutical major Eli Lily will enter the general practitioners' market for the first time, Newton Crenshow, president of Eli Lilly Japan, said at a press conference to announce the introduction of the ED drug, which is the third in the PDE-5 inhibitors, following Pfizer's Viagra (sildenafil) and Bayer's Levitra (vardenafil) on this market.
Eli Lilly Japan is aiming to get its drug in the top 20 by 2010 and the top 15 by 2015, respectively, by focusing on the therapeutic fields of the central nervous system, endocrinology, osteoporosis and cancer based on its organic growth.
The company sees its entrance into the GP market as one of the measures to reach the goals.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze